Navigation Links
New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearch's cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery

PARIS, July 19 /PRNewswire-FirstCall/ -- Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), today announced the publication of a scientific study describing a novel method, based on meganuclease-driven targeted integration, for the generation of stable cell lines compatible with high throughput screening (HTS)(1). The study demonstrated Cellectis bioresearch's technology to be faster, more reliable and efficient in deriving cell-based assays for HTS studies than classical methods. The study has been published online by Journal of Biomolecular Screening

The development of cell-based assays for HTS approaches is important to screen molecules on pharmaceutical targets and often requires the generation of stable cell lines. However, these cell lines are essentially created by random integration of a gene of interest (GOI) with no control over the level and stability of gene expression. In this study, scientists from the Servier Research institute used Cellectis bioresearch's cellular Genome Positioning System, or cGPS®, in CHO-K1 cells, to accomplish targeted integration of different GOIs. Five different GOIs representing 3 major drug target classes were stably integrated at the same locus in cGPS® CHO-K1 cells. Characterization of the targeted clones revealed that the cGPS® CHO-K1 system was more rapid (2-week protocol), efficient (all selected clones expressed the GOI), reproducible (GOI expression level variation of 12% maximum), and stable over time (no change in GOI expression after 23 weeks of culture) than classical random integration.

"Achieving a physiological level of expression compatible with the relevant functional assay is important in testing pharmaceutical targets", explained Jean Boutin, Director of the Molecular and Cellular Pharmacology Division of the SERVIER Research Institute. "We found that proteins expressed in the cGPS® CHO-K1 cells are biologically active and have enzymatic constants, localization and function close to the published values of their wild-type endogenous counterparts. This fast and robust method opens the door for creating large collections of cell lines expressing therapeutically relevant GOIs, enhancing the productivity of HTS".

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with ready-to-use research tools for genome customization.  These tools, based on meganucleases, enable the customization of cells with optimized features for drug discovery, protein production and gene function study.

More information at

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at


This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) JP Cabaniols et al. Meganuclease-driven targeted integration in CHO-K1 cells fort he fast generation of HTS compatible cell-based assays. Journal of Biomolecular Screening 2010, doi:10.1177/1087057110375115

SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
2. Worlds Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients
3. Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology
4. 12-Month Study Reports 90% Success Rate for AMS MiniArc Single-Incision Sling
5. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
6. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
7. Drug Study Shows Improvement in Major Orthopedic Surgery Care
8. Enrollment Underway in CLARITY-AF Study to Compare Efficacy, Safety and Efficiency of Two Catheter Ablation Technologies
9. Nile Therapeutics Completes Dosing of Phase II Study
10. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
11. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
Post Your Comments:
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):